CoChat
Sign Up
Cited by 84Diabetes and associated disordersDiabetes Management and ResearchDiabetes Treatment and Management

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Classifying diabetes according to the new WHO clinical stages

Lindholm, E., Agardh, E., Tuomi, T., Groop, L., Agardh, C.-D.·2001·European Journal of Epidemiology
DOI 10.1023/a:1020036805655
Open this paper in CoChat — free account

Abstract

Aims/hypothesis To test the usefulness of the new WHO criteria for clinical staging of diabetes in the characterization of 1977 diabetic patients. Methods The following clinical stages were used: patients on diet and/or oral antidiabetic agents 2 years after diagnosis were considered as non-insulin requiring (NIR; n = 711) and patients who required insulin therapy after 1 year as insulin requiring for control (IRC; n = 543). Patients who because of deteriorating hyperglycemia within 1 year required insulin therapy were considered as insulin requiring for survival (IRS; n = 743). Results The NIR patients had the highest age at onset (52 +/- 12 years; mean +/- SD), BMI (29.3 +/- 5.2 kg/m2) and C-peptide concentrations (median 0.98 nmol/l; interquartile range 0.72-1.31 nmol/l) but the lowest frequency of GAD antibodies (5.5%) compared to the IRC and IRS groups. The IRC group had a high age at onset (49 +/- 13 years), BMI (28.0 +/- 4.8 kg/m2), frequency of GAD antibodies (16.8%), intermediate C-peptide concentrations (0.56 nmol/l, interquartile range 0.28 +/- 0.94), and the highest prevalence of nephropathy (31.5%) and neuropathy (68.1%). The IRS group had the lowest age at onset (23 +/- 15 years), BMI (24.2 +/- 3.4 kg/m2), C-peptide concentrations (0.05 nmol/l, interquartile range below detection limit 0.01) and highest frequency of GAD antibodies (44.5%). Retinopathy was more common in IRS than in IRC patients (62.1 vs. 43.9%;p Conclusions The new WHO criteria seem to discrimin…

Overview

Integrity signals

Registry

Crossref · 10.1023/a:1020036805655

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Given strict HbA1c criteria for new-onset diabetes in the MHR and the requirement of physician diagnosis in NDR and Diabetes 2000, those classified as new-onset diabetes cases are unlikely to be misclassified.

    “On the other hand, given the strict HbA1c criteria for new-onset diabetes in the MHR and the fact that the NDR and Diabetes 2000 registers require a physician diagnosis according to established diagnostic criteria,28, 29 those classified as new-onset diabetes cases in our study are unlikely to be misclassified.”

    From Plasma Copeptin and the Risk of Diabetes Mellitus (2010) · cites this paper as [29]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. WHO Study Group (1985) in World Health Organization Technical Report Series 727 (World Health Organization, Geneva).

Cited by

Sorted by citations

Related

Metadata

Authors
Lindholm, E., Agardh, E., Tuomi, T., Groop, L., & Agardh, C.-D.
ORCID
Venue
European Journal of Epidemiology
Publisher
Springer Science and Business Media LLC
Published
2001-11
Volume
17
Issue
11
Pages
983-989
ISSN
  • 0393-2990 (ISSN-L)
  • 1573-7284
DOI
10.1023/a:1020036805655
OpenAlex
W1960743603
Semantic Scholar
8f224af55ca98bc4f9a0d8adc3d36176ebada5c7
Cited by
82
References
13
Citations by year
2024: 5 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 1 · 2018: 9 · 2017: 5 · 2016: 6 · 2015: 3 · 2014: 8 · 2013: 2 · 2012: 12
FWCI
0.36
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • European Journal of Epidemiology (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
diabetes mellitus, WHO clinical stage, insulin requirement, glutamic acid decarboxylase antibodies, C-peptide, age of onset, body mass index, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, disease severity classification
MeSH terms
Aged, Autoantibodies, C-Peptide, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Glutamate Decarboxylase, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Sweden, World Health Organization, Biomarkers, Guidelines as Topic, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review